Published in

Oxford University Press, The Journal of Infectious Diseases, 11(205), p. 1705-1708, 2012

DOI: 10.1093/infdis/jis269

Links

Tools

Export citation

Search in Google Scholar

Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)

Journal article published in 2012 by Mamoudou Maiga, Shichun Lun, Haidan Guo, Kathryn Winglee ORCID, Nicole C. Ammerman, William R. Bishai
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.